The European Commission has granted a EUROSTARS grant to AlveoliX and twelve further Swiss startups. The selected companies are united by one common characteristic: they all leverage high-tech technologies in their designated fields of medtech, biotech, additive manufacturing, nano-technology among others.
EUROSTARS is a joint initiative co-funded from the national budgets of 36 Eurostars and by the European Union through Horizon 2020. In the 2014-2020 period, the program has a total public budget of €1.14 billion.
By providing financial aid, the initiative enables R&D-performing SMEs and research institutes from Eurostars participating states and partner countries to focus on their market-oriented research and development as well as improve their performance.
In the 2019 cutoff, 20 projects led by Swiss startups and research institutes received the grants. The 2019 Eurostars Startups and projects includes AlveoliX. AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making. The Eurostars project, AIM4DOC, will support the company in developing an Advanced Inhalation Model for Drug Discovery on Chip.
